U.S. FDA Panel Backs Novartis AG (JOBS) Transplant Drug

Bookmark and Share

Reuters -- A U.S. advisory panel recommended approval of a Novartis AG drug to prevent rejection of transplanted kidneys, a Food and Drug Administration spokeswoman said on Monday.
MORE ON THIS TOPIC